Published in Clinical Oncology Week, September 4th, 2006
According to recent research from Ireland, "Advanced prostate cancer is not curable by current treatment strategies indicating a significant need for new chemotherapeutic options. Highly substituted ansatitanocene compounds have shown promising cytotoxic activity in a range of cancers."
"The objectives of this study are to examine the effects of these titanocene compounds on prostate cancer cells," explained K. O'Connor and colleagues, University College Dublin. "Prostate cell lines were treated with 3 novel titanocene compounds and compared to titanocene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.